Single-agent and combination chemotherapy with etoposide in the acute leukemias of childhood

G. Rivera, Paul Bowman, A. T. Look, W. E. Evans, D. Kalwinsky, G. V. Dahl

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

In clinical trials conducted at St Jude Children's Research Hospital, etoposide has proved to be an effective agent for the treatment of advanced childhood leukemias. When combined with 5-azacytidine, it induced complete remissions in about one-half of patients with refractory ANLL. The same induction rate was achieved in patients with refractory ALL receiving etoposide with prednisone and vincristine. Results of continuing studies should help to identify the optimal schedules and dosages for this epipodophyllotoxin. The acceptance of new antileukemic drugs into clinical practice has slowed over the past decade. Etoposide is but one of several new agents that hold promise of moving leukemia therapy beyond its present barriers.

Original languageEnglish
Pages (from-to)53-57
Number of pages5
JournalCancer Treatment Reviews
Volume9
Issue numberSUPPL. 1
DOIs
StatePublished - 1 Jan 1982

Fingerprint

Etoposide
Combination Drug Therapy
Leukemia
Podophyllotoxin
Azacitidine
Vincristine
Prednisone
Acute Myeloid Leukemia
Appointments and Schedules
Clinical Trials
Therapeutics
Research
Pharmaceutical Preparations

Cite this

Rivera, G. ; Bowman, Paul ; Look, A. T. ; Evans, W. E. ; Kalwinsky, D. ; Dahl, G. V. / Single-agent and combination chemotherapy with etoposide in the acute leukemias of childhood. In: Cancer Treatment Reviews. 1982 ; Vol. 9, No. SUPPL. 1. pp. 53-57.
@article{c7481d0bbed548e3b3260824c5f1b361,
title = "Single-agent and combination chemotherapy with etoposide in the acute leukemias of childhood",
abstract = "In clinical trials conducted at St Jude Children's Research Hospital, etoposide has proved to be an effective agent for the treatment of advanced childhood leukemias. When combined with 5-azacytidine, it induced complete remissions in about one-half of patients with refractory ANLL. The same induction rate was achieved in patients with refractory ALL receiving etoposide with prednisone and vincristine. Results of continuing studies should help to identify the optimal schedules and dosages for this epipodophyllotoxin. The acceptance of new antileukemic drugs into clinical practice has slowed over the past decade. Etoposide is but one of several new agents that hold promise of moving leukemia therapy beyond its present barriers.",
author = "G. Rivera and Paul Bowman and Look, {A. T.} and Evans, {W. E.} and D. Kalwinsky and Dahl, {G. V.}",
year = "1982",
month = "1",
day = "1",
doi = "10.1016/S0305-7372(82)80078-9",
language = "English",
volume = "9",
pages = "53--57",
journal = "Cancer Treatment Reviews",
issn = "0305-7372",
publisher = "W.B. Saunders Ltd",
number = "SUPPL. 1",

}

Single-agent and combination chemotherapy with etoposide in the acute leukemias of childhood. / Rivera, G.; Bowman, Paul; Look, A. T.; Evans, W. E.; Kalwinsky, D.; Dahl, G. V.

In: Cancer Treatment Reviews, Vol. 9, No. SUPPL. 1, 01.01.1982, p. 53-57.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Single-agent and combination chemotherapy with etoposide in the acute leukemias of childhood

AU - Rivera, G.

AU - Bowman, Paul

AU - Look, A. T.

AU - Evans, W. E.

AU - Kalwinsky, D.

AU - Dahl, G. V.

PY - 1982/1/1

Y1 - 1982/1/1

N2 - In clinical trials conducted at St Jude Children's Research Hospital, etoposide has proved to be an effective agent for the treatment of advanced childhood leukemias. When combined with 5-azacytidine, it induced complete remissions in about one-half of patients with refractory ANLL. The same induction rate was achieved in patients with refractory ALL receiving etoposide with prednisone and vincristine. Results of continuing studies should help to identify the optimal schedules and dosages for this epipodophyllotoxin. The acceptance of new antileukemic drugs into clinical practice has slowed over the past decade. Etoposide is but one of several new agents that hold promise of moving leukemia therapy beyond its present barriers.

AB - In clinical trials conducted at St Jude Children's Research Hospital, etoposide has proved to be an effective agent for the treatment of advanced childhood leukemias. When combined with 5-azacytidine, it induced complete remissions in about one-half of patients with refractory ANLL. The same induction rate was achieved in patients with refractory ALL receiving etoposide with prednisone and vincristine. Results of continuing studies should help to identify the optimal schedules and dosages for this epipodophyllotoxin. The acceptance of new antileukemic drugs into clinical practice has slowed over the past decade. Etoposide is but one of several new agents that hold promise of moving leukemia therapy beyond its present barriers.

UR - http://www.scopus.com/inward/record.url?scp=0020427484&partnerID=8YFLogxK

U2 - 10.1016/S0305-7372(82)80078-9

DO - 10.1016/S0305-7372(82)80078-9

M3 - Article

C2 - 6181873

AN - SCOPUS:0020427484

VL - 9

SP - 53

EP - 57

JO - Cancer Treatment Reviews

JF - Cancer Treatment Reviews

SN - 0305-7372

IS - SUPPL. 1

ER -